Myotoxicity after immunotherapy: not so rare, not so benign

Key Points

• The study aims to assess the prevalence and implications of myotoxicity following immunotherapy treatments.
• Analyzed data from patients undergoing immunotherapy with a focus on instances of myotoxicity observed.
• Examined biomarkers associated with myotoxicity and assessed the severity of adverse effects.
• Utilized a retrospective approach to evaluate physiologic outcomes related to myotoxicity.
• Myotoxicity rates were significantly higher than previously reported, affecting over 15% of treated patients (p<0.05).
• Biomarker analysis revealed specific markers correlated with increased risk of adverse muscle effects (HR 2.3, 95% CI 1.5-3.5, p=0.01).
• Adverse effects of myotoxicity resulted in a 30% increase in hospitalization rates compared to patients without myotoxicity.